ESEkaterina Salnikova

Ekaterina Salnikova

*This is an algorithmically generated author record based on publicly available information.

Ekaterina Salnikova has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Myxopapillary ependymomas in children: clinical, morphological characteristics and treatment outcomes

    by Igor N. Kasich, Касич Игорь Николаевич, A. E. Druy, Друй А. Е., A. V. Protsvetkina, Процветкина А. В., A. V. Tarakanova, Тараканова А. В., A. V. Artyomov, Артемов А. В., et al.

    Introduction. Myxopapillary ependymoma (MPE) is a rare ependymal neoplasm arising predominantly from the conus medullaris, cauda equina, and filum terminale. In the pediatric population, MPE accounts for less than 10% of all ependymomas and approximately 1–2% of all primary central nervous system tumors. Compared to adults, pediatric MPE displays a more aggressive clinical course, with higher rates of leptomeningeal dissemination at diagnosis (reported in up to 35–58% of cases in some series) and higher rates of local and metastatic recurrence following surgical treatment. In accordance with the 2021 World Health Organization Classification of Central Nervous System Tumors, MPE has been reclassified as a Grade 2 neoplasm. Large pediatric cohorts with concurrent analysis of clinical and morphological features and treatment outcomes remain scarce, and national data from Russian institutions are virtually absent from the international literature. The aim of this study was to analyze the clinical and morphological characteristics of pediatric MPE and to evaluate the impact of extent of surgical resection and radiation therapy (RT) on disease outcomes. Materials and methods. This retrospective study included 49 patients under 18 years of age with histologically confirmed MPE at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) between 2013 and 2025. Parameters analyzed included patient demographics, tumor localization, metastatic staging per Chang classification (M0–M3), extent of surgical resection, use of RT. The primary endpoint was event-free survival (EFS), defined as time from diagnosis to disease progression or relapse. A morphological sub-analysis was performed in 28 patients with available archival histological material, evaluating candidate anaplasia features: high cellularity, mucin reduction, high mitotic activity (≥5 mitoses per high-power field at ×400 or Ki-67 ≥10%), endothelial proliferation, spontaneous necrosis, and heterogeneous GFAP expression. A composite anaplasia index was calculated. Statistical analyses were performed in R 4.5.2 using Kaplan–Meier estimation, log-rank testing, and multivariate Cox proportional-hazards regression. Results. Of 49 patients, 57.1% were male and the median age at diagnosis was 12.8 years (range 5.8–18.0). The predominant tumor location was the lumbosacral spinal cord (85.7%). Metastatic dissemination at diagnosis was identified in 8/49 (16.3%) patients. Gross total resection was achieved in 28/49 (57.1%) patients. RT was administered to 23/49 (46.9%) patients. At the time of analysis, all 49 patients were alive (overall survival – 100%), with a median follow-up of 4.2 years. Disease progression or relapse occurred in 12/49 (24.5%) patients. The 3- and 5-year EFS for the entire cohort were 77.6% and 69.4%, respectively. On multivariate Cox analysis, adjuvant RT was an independent statistically significant predictor of EFS (hazard ratio 0.05; 95% confidence interval 0.01–0.44; p = 0.007). The greatest benefit from RT was observed in patients with incomplete resection: 5-year EFS increased from 22.2% with surgery alone to 66.7% with the addition of RT. In contrast, patients achieving R0 resection without RT already demonstrated a favorable 5-year EFS of 75.6%. In the morphological subgroup, a composite anaplasia index ≥2 was significantly associated with inferior EFS: 44.0% vs. 81.0% (log-rank p = 0.046; adjusted hazard ratio 4.44; 95% confidence interval 1.04–19.0; p = 0.044). Conclusion. Pediatric MPE is characterized by excellent overall survival but heterogeneous EFS outcomes determined primarily by extent of resection and adjuvant RT. A risk-adapted strategy – reserving RT for patients with residual disease – is supported by the results of this study and is consistent with EANO guidelines for spinal ependymomas. Routine RT following gross total resection appears unnecessary, given the well-documented long-term radiation toxicity in growing children. The proposed composite morphological anaplasia index represents a promising tool for additional risk stratification in pediatric MPE, pending validation in larger, prospective, and preferably multicenter cohorts.

  • Open Access

    Extraneural myxopapillary ependymomas in children: a case series and literature review

    by I. N. Kasich, A. E. Druy, M. A. Zaytseva, A. V. Tarakanova, A. V. Artyomov, M. V. Demchenkova, V. A. Filimonenkova, D. L. Sakun, E. A. Salnikova, A. E. Sysoev, et al.

    Background . Extraneural myxopapillary ependymomas (MPE) of the sacrococcygeal region are ultra-rare ependymal tumors with a marked pediatric predominance; no more than 36 pediatric cases have been reported in the world literature. Materials and methods . We performed a retrospective analysis of 5 pediatric patients with extraneural MPE diagnosed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) between 2015 and 2024. All patients were girls, the median age at diagnosis was 8.3 years (range – 4.9–15.3 years). Results . In 4 (80 %) of 5 patients, the tumor was located subcutaneously in the sacrococcygeal or intergluteal region; in 1 case it was presacral. A primary diagnostic error was recorded in 3 (60 %) patients, incorrect diagnoses were soft tissue sarcoma, primitive neuroectodermal tumor/immature teratoma, and clear cell ependymoma. All 5 tumors were morphologically consistent with MPE WHO grade 2 with diffuse GFAP expression. Molecular profiling by targeted gene expression profiling (NanoString technology) was performed in 4 of 5 (80 %) patients and confirmed the diagnosis of MPE in all cases. Radical resection was achieved in 4 patients (80 %); none of them developed recurrence. The single patient with R+ resection demonstrated disease progression. At a median follow-up of 43.0 months, all 5 patients are alive. Conclusions . Extraneural MPEs are characterized by a high rate of diagnostic errors and require mandatory histological review in a specialized reference center. Molecular genetic profiling using NanoString technology confirms the diagnosis and demonstrates the molecular relatedness of extraneural MPEs to their spinal counterparts. Radical resection is the key prognostic factor. Because of the risk of late metastatic spread, lifelong follow-up is required.

  • Open Access

    Long-term toxicities of chemoradiotherapy in children with standard-risk medulloblastoma

    by A. N. Flegontov, A. E. Druy, A. V. Protsvetkina, D. R. Gaynullina, M. A. Evdokimova, E. Yu. Ilyina, A. V. Artyomov, V. V. Gornostaev, Е. А. Сальникова, A. E. Sysoev, et al.

    Background. Medulloblastoma (MB) is one of the most common malignant brain tumors in children. In the standard-risk group, 5-year overall survival reaches 75–85 %, however, high treatment efficacy is accompanied by a considerable risk of late toxic effects that substantially impact patients’ quality of life. The most prevalent complications include cognitive and endocrine disorders, sensorineural hearing loss, and scoliosis. Long-term follow-up of survivors remains non-standardized. The aim of this study was to comprehensively assess the spectrum and frequency of late effects after chemoradiotherapy in children with standard-risk MB and to identify factors influencing their development. Materials and methods . A retrospective analysis was performed in 144 patients with standard-risk MB treated at the Dmitry Rogachev National Medical Research Center between 2013 and 2023. All patients received craniospinal irradiation at a dose of 23.4–24.0 Gy or 35.2–36.0 Gy with a posterior fossa boost to 54–55 Gy, followed by maintenance chemotherapy (lomustine, cisplatin, vincristine). To assess late effects (endocrine dysfunction, sensorineural hearing loss, scoliosis, chronic nutritional deficiency, polyneuropathy), detailed clinical and laboratory data were available for 55 patients, neurocognitive outcomes were analyzed in 30, and oncologic follow-up for secondary tumors in all 144. The cumulative incidence of complications was estimated using competing-risks methodology, subgroup comparisons were performed with Gray’s test, with p < 0.05 considered statistically significant. Results. The median age at the start of radiotherapy was 8.2 years, median follow-up 3.2 years. The most frequent late effects were cognitive (96.7 %) and endocrine disorders (89.1 %). Less frequent complications included scoliosis (50.9 %), sensorineural hearing loss (47.3 %), nutritional deficiency (32.7 %), and polyneuropathy (25.5 %), secondary neoplasms occurred in 4.2 % of patients. The most common cognitive impairments involved reduced psychomotor speed, attention, memory, emotional stability, and learning ability. Following therapy, a statistically significant increase was observed in the frequency of memory impairment (p = 0.01) and learning difficulties (p = 0.027). Growth hormone deficiency was detected in 70.1 % of patients (median time to onset – 1.7 years), the diagnosis was confirmed in 43 %, and growth hormones replacement therapy was initiated in only one-third. Hypothyroidism was diagnosed in 69.1 %, secondary adrenal insufficiency in 21.8 %, and gonadal dysfunction in 16.4 %. Growth hormone deficiency and hypothyroidism developed significantly earlier in patients who received craniospinal irradiation 35.2 Gy, although their long-term cumulative incidence was similar to those treated with 23.4 Gy. The 6-year cumulative incidence of secondary neoplasms was 4.7 %; most were high-grade diffuse gliomas (n = 3) with a median survival not exceeding one year. Conclusion s. Chemoradiotherapy for standard-risk MB is associated with a wide spectrum of late toxicities, predominantly cognitive and endocrine, most of which can be effectively managed when detected in a timely manner. Unwarranted de-escalation of therapy without reliable prognostic justification is unacceptable due to the high risk of fatal relapse. Systematic long-term monitoring of late effects, application of modern toxicity-reduction approaches, and comprehensive rehabilitation programs are essential components of optimal survivorship care for patients with MB.

  • Open Access

    Treatment outcomes in standard-risk medulloblastoma patients: the role of molecular genetic stratifications

    by Andrey N. Flegontov, A. E. Druy, A. V. Protsvetkina, M. A. Zaytseva, N. V. Gegeliya, V. S. Petrova, M. A. Senchenko, A. V. Tarakanova, A. V. Sanakoeva, A. V. Artyomov, et al.

    Introduction. Medulloblastoma (MB) is a clinically and biologically heterogeneous tumor of the central nervous system (CNS); however, current risk stratification criteria rely primarily on its clinical and morphological features. The aim of the study was to assess molecular and genetic characteristics of MB in standard risk group patients and analyze their impact on the clinical course of the disease and long-term treatment outcomes. Materials and methods. This retrospective study included 137 patients with standard-risk MB according to the criteria in the HIT-MED 2020. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. All the patients underwent molecular subgrouping (WNT, SHH, Group 3, or Group 4). Overall survival (OS), event-free survival (EFS), and relapse characteristics were assessed in relation to molecular subgroup, craniospinal irradiation (CSI) dose, and time to the start of radiotherapy. Results. Five-year OS and EFS rates for the entire cohort were 84% and 74%, respectively. The most favorable outcomes were observed in the WNT subgroup (OS 93%, EFS 86%); however, recurrences occurred in 14.6% of the patients, exclusively among those who received a CSI dose of 23.4 Gy. In the SHH subgroup, the recurrence rate was 39.1% and was associated with the presence of TP53 mutations. CSI dose escalation of did not improve survival in this subgroup. Patients in Group 3 had the poorest prognosis, with a high rate of early metastatic relapses, particularly among those treated with a CSI dose of 23.4 Gy. Patients in Group 4 had intermediate survival and a moderate recurrence rate (22%). Neither CSI dose nor the time to the start of radiation therapy had a significant impact on survival in the entire cohort. Conclusion. Molecular subgroups are an important prognostic factor even in patients with favorable clinical and morphological profiles. Our findings support the need to integrate molecular stratification into routine clinical practice and to be careful when considering de-escalation or intensification of treatment strategies in the standard-risk group.

  • Open Access

    Tumor predisposition syndromes in patients with SHH group medulloblastoma

    by Marina M. Koldasheva, L. I. Papusha, E. A. Salnikova, A. E. Druy, M. A. Kurnikova, G. A. Novichkova, N. S. Grachev, L. A. Yasko

    Introduction. Medulloblastomas (MB) of the SHH group account for 25–30% of all MBs and are associated with aberrant activation of the intracellular SHH signaling pathway. The incidence of tumor predisposition syndromes (TPS) in patients with MB of the SHH group is about 20%, and this is the highest rate among the other molecular genetic subgroups of MB. In addition, there is significant molecular genetic heterogeneity within the same group, which in turn contributes to variations in survival rates and prognosis. Objective – to analyze the clinical, molecular, and genetic characteristics of TPS in patients with SHH group MB. Materials and methods. This retrospective study included a cohort of 40 patients aged 0 to 18 years with SHH group MB who underwent molecular genetic diagnostic testing between 2018 and 2024 at the D. Rogachev National Medical Research Center. The MB group was determined using NanoString technology. To identify germline mutations, DNA isolated from peripheral blood was examined using the following methods: next-generation sequencing, whole genome sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification. The amplification of the MYC and NMYC genes was detected using fluorescence in situ hybridization. This study did not require approval from the local Ethics Committee, as the analyzed data did not contain any personalized information. Consent was obtained for the peripheral blood testing for TPS and for the publication of the data. Statistical processing and analysis of the data obtained were carried out using the R package version 4.4.2. Overall survival was estimated using the Kaplan–Meier method, and the cumulative incidence of secondary tumors was estimated using the competing risk method. To calculate the overall survival, we used the time from the date of diagnosis to death, and for the cumulative incidence of secondary tumors, we used the time from the date of diagnosis to the development of a secondary tumor, while death was considered a competing event. Results. Fifteen out of 40 patients were diagnosed with TPS. Gorlin syndrome was diagnosed in 7 people, Li–Fraumeni syndrome in 4 patients, there was one case each of Lynch syndrome and neurofibromatosis type 1, and a mutation in the ELP1 gene. One child had a combination of two syndromes (Gorlin and Lynch). The incidence of TPS in the analyzed cohort of 40 people was 37.5%. Thirteen people are alive, 2 patients died. The overall 4-year survival rate was 93% (the 95% confidence interval 82–100). A secondary tumor developed in 4 patients. The 4-year cumulative incidence of secondary tumors was 31% (the 95% confidence interval 6.4–61.0). All patients who developed a secondary tumor had received radiation therapy. Conclusion. When detecting MB of the SHH, it is important to conduct molecular genetic testing for TPS, given their high frequency among patients with MB of this molecular subgroup. The data obtained will help optimize therapy (avoid radiation therapy for young children with confirmed Gorlin syndrome), as well as predict the course of the disease. In addition, genetic testing is necessary for follow-up of such patients and for counseling their parents regarding the familial forms of the described syndromes.

  • Open Access

    Current approaches to the treatment of Ewing sarcoma in children and adolescents

    by Irina G. Vilesova, E. A. Salnikova, A. V. Pshonkin, E. I. Konopleva, A. I. Karachunskiy

    Ewing sarcoma (ES) is a rare and aggressive malignant tumor that mostly affects the bones. It is characterized by a translocation fusing a member of the FET family and one of the genes of the ETS family. The tumor requires multimodality treatment that includes chemotherapy and adequate local control (surgery and/or radiation therapy). Here, our goal was to report on current treatment approaches for ES in children and adolescents. Presently, an intensified VDC (vincristine, doxorubicin, сyclophosphamide)/IE (ifosfamide, etoposide) regimen with cycles given every 14 days is the preferred neoadjuvant chemotherapy option. Highdose chemotherapy was found to be effective in the treatment of patients with high-risk localized ES. In disseminated ES, this treatment is ineffective and hence is not used. Metronomic therapy that can include both low-dose chemotherapy and targeted drugs is prescribed to patients with relapsed/refractory ES, as well as to primary patients with initially metastatic disease.

  • Open Access

    Low-grade gliomas of the brainstem in children: stratification into risk groups and the assessment of the effectiveness of targeted therapy

    by L. I. Papusha, A. E. Druy, Е. А. Сальникова, A. A. Merishavyan, A. V. Sanakoeva, А. V. Artemov, I. N. Kasich, I. G. Vilesova, A. N. Flegontov, A. V. Protsvetkina, et al.

    Low-grade gliomas (LGG) of the brainstem remain a therapeutic challenge due to the impossibility of radical tumor resection and unsatisfactory results of standard treatment. We aimed to analyse clinical molecular genetic characteristics of patients with LGG of the brainstem and the results of standard treatment according to the SIOP-LGG protocol as well as targeted therapy with BRAF and MEK inhibitors. The study included 59 patients with sporadic (non-neurofibromatosis type I) LGG of the brainstem. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The patients' legal representatives gave their informed consent to the use of the patients' data for research purposes and in publications. The 8-year overall survival rates were 68% (47–96%) and the 5-year progression-free survival (PFS) rates were 38% (26–57%). The medulla oblongata was the most common tumor site (n = 25; 40%), in 21 (35.5%) cases, the tumor spread to the adjacent structures of the brainstem and brain. Radical resection of the tumor was performed in 14 patients, subtotal resection – in 15 patients, partial resection – in 14, and 16 patients underwent biopsy. In most cases, the histological type of the tumor was pilocytic astrocytoma (n = 49; 83%). The KIAA1549::BRAF chimeric transcript was detected in the majority of patients (n = 33; 56%). The BRAFV600E mutation was found in 12 (22%) patients, the H3K27M mutation – in 4 (7%) patients. Twelve patients received chemotherapy according to the SIOP-LGG protocol (carboplatin + vincristine). The 2-year PFS rates were 44% (22–87%). Local radiotherapy was performed in 12 patients. The 2-year PFS rates were 44% (22–87%). Targeted therapy with the MEK inhibitor (trametinib) was prescribed to 13 patients, combination therapy with the BRAF and MEK inhibitors – to 9 patients, and one patient was prescribed BRAF inhibitor (vemurafenib) monotherapy. The 2-year PFS in the patients treated with first-line targeted therapy was 88% (67–100%). The most common adverse event of targeted therapy was skin toxicity (70%). A multivariate analysis revealed that the prognostically significant factors influencing PFS were the extent of resection and a molecular genetic driver: biopsy and partial resection of the tumor, as well as the presence of the BRAFV600E and H3K27M mutations demonstrated an independent negative prognostic value.


  • Open Access

    Epidemiology, clinical features and prognosis for medulloblastoma relapse depending on the molecular subgroups in children and adolescents

    by A. E. Sysoev, L. I. Papusha, A. I. Karachunskiy, A. V. Protsvetkina, N. B. Yudina, L. G. Fechina, G. R. Kazaryan, O. E. Nikonova, A. A. Merishavyan, I. G. Vilesova, et al.

    The 2016 World Health Organization classification of central nervous system tumors for the first time provided the division of medulloblastoma (MB) into molecular subgroups which determine treatment response, the likelihood of relapse, the outcome of the disease and prognosis. The course of the disease and prognosis are also expected to be influenced by a number of genetic factors, such as the amplification of the MYC family genes and mutations in the TP53 gene. MB relapse has a heterogeneous clinical course, poor prognosis and continues to be a therapeutic challenge. We conducted retrospective and prospective analyses of the data from the group of 50 pediatric and adolescent patients with MB relapse. A morphology review and the determination of molecular subgroups were performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow, Russia) from January 2014 to December 2023. The aim of the study is to identify the specific differences in MB relapse in 50 pediatric and adolescent patients, depending on their molecular subgroup. An anatomical site of relapse, time to relapse, postrelapse survival and the effectiveness of various relapse treatment regimens were studied. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.

  • Open Access

    A rare case of metastatic involvement of the bone marrow in a patient with medulloblastoma

    by T. V. Konyukhova, I. G. Vilesova, Е. А. Сальникова, A. V. Artemov, A. P. Shcherbakov, L. I. Papusha

    Extraneural metastasis from primary brain tumors is an extremely rare occurrence. The majority of such cases described in the literature are medulloblastoma relapses. In this article, we report a case of relapse in a patient with medulloblastoma with the metastatic involvement of the bone marrow two years after successful treatment for the primary tumor. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.

  • Open Access

    High-dose chemotherapy with autologous hematopoietic stem cell transplantation in the treatment of recurrent medulloblastoma in children

    by A. E. Sysoev, L. I. Papusha, Е. А. Сальникова, A. V. Protsvetkina, A. A. Merishavyan, I. G. Vilesova, G. V. Tereshchenko, A. I. Karachunskiy

    Medulloblastoma (MB) recurrence can manifest in various clinical ways and still remains a major therapeutic challenge. As reported in the international literature, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT) has low effectiveness and severe toxicity in patients with recurrent MB. Here, we analyzed the effectiveness and tolerability of HDCT with auto-HSCT in 9 pediatric and adolescent patients with MB relapses whose histological samples and magnetic resonance images had been reviewed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from July 2013 till December 2021. The aim of the study was to evaluate the effectiveness of the HDCT with auto-HSCT approach for the treatment of MB relapses in pediatric patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia.